We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-20.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$268M
AUM Growth
-$125M
(-32%)
Cap. Flow
-$27.2M
Cap. Flow
% of AUM
-10.13%
Top 10 Holdings %
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14
Avg Time Held
4
quarters
Top 10 Avg Time Held
5.1
quarters
Top 20 Avg Time Held
5.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalo Therapeutics
AVTX
|
+$8.46M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$7.06M |
| 3 |
Immunogen Inc
IMGN
|
+$6.2M |
| 4 |
Abeona Therapeutics
ABEO
|
+$3.93M |
| 5 |
AIMT
Aimmune Therapeutics
AIMT
|
+$3.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$10M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$8.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$7.01M |
| 4 |
Amarin Corp
AMRN
|
+$6.38M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$6.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Codexis
CDXS
$154M
| $29.2M | 10.91% |
1,750,000
| – | – |
2014 Q1
19 quarters
|
|
2
Axogen
AXGN
$2.18B
| $26.6M | 9.91% |
1,300,000
| – | – |
2015 Q1
15 quarters
|
|
|
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
| $24.5M | 9.15% |
175,000
| – | – |
2016 Q3
9 quarters
|
|
|
4
Amarin Corp
AMRN
$254M
| $17M | 6.35% |
62,500
-17,500
| -22% | -$6.38M |
2017 Q4
4 quarters
|
|
5
DELISTED
Blueprint Medicines
BPMC
| $16.2M | 6.04% |
300,000
| – | – |
2015 Q3
13 quarters
|
|
6
Harrow
HROW
$1.09B
| $9.8M | 3.66% |
1,722,000
+102,000
| +6% | +$437K |
2018 Q3
1 quarter
|
|
7
Kyntra Bio
KYNB
$24.8M
| $9.26M | 3.45% |
8,000
| – | – |
2014 Q4
16 quarters
|
|
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.14M | 2.66% |
340,000
-80,000
| -19% | -$1.97M |
2018 Q1
3 quarters
|
|
|
EPZM
9
DELISTED
Epizyme, Inc
EPZM
| $6.93M | 2.59% |
1,125,000
+925,000
| +463% | +$7.06M |
2018 Q1
3 quarters
|
|
10
PTC Therapeutics
PTCT
$5.25B
| $6.52M | 2.43% |
190,000
+10,000
| +6% | +$360K |
2018 Q1
3 quarters
|
|
11
Xencor
XNCR
$1.86B
| $6.51M | 2.43% |
180,000
| – | – |
2018 Q2
2 quarters
|
|
12
Viking Therapeutics
VKTX
$3.6B
| $6.31M | 2.36% |
825,000
| – | – |
2017 Q4
4 quarters
|
|
|
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
| $6.23M | 2.32% |
1,390,000
-340,000
| -20% | -$1.66M |
2016 Q4
8 quarters
|
|
|
14
Avalo Therapeutics
AVTX
$710M
| $6.21M | 2.32% |
+759
| New | +$8.46M |
2018 Q4
0 quarters
|
|
15
Fennec Pharmaceuticals
FENC
$376M
| $5.74M | 2.14% |
900,000
-75,000
| -8% | -$524K |
2017 Q4
4 quarters
|
|
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $5.74M | 2.14% |
500,000
+10,000
| +2% | +$124K |
2016 Q4
8 quarters
|
|
17
DELISTED
Cymabay Therapeutics
CBAY
| $5.71M | 2.13% |
725,000
+26,900
| +4% | +$256K |
2017 Q3
5 quarters
|
|
|
PTE
18
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $5.4M | 2.01% |
16,000
-14,600
| -48% | -$5.28M |
2018 Q2
2 quarters
|
|
19
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.33M | 1.99% |
250,000
+25,000
| +11% | +$645K |
2017 Q2
6 quarters
|
|
20
DELISTED
Chimerix, Inc.
CMRX
| $5.19M | 1.94% |
2,020,000
+835,000
| +70% | +$2.8M |
2016 Q1
11 quarters
|
|
21
DELISTED
Xoma
XOMA
| $5.06M | 1.89% |
400,000
+80,000
| +25% | +$1.14M |
2017 Q1
7 quarters
|
|
|
22
DELISTED
Immunogen Inc
IMGN
| $4.9M | 1.83% |
+1,021,000
| New | +$6.2M |
2018 Q4
0 quarters
|
|
23
DELISTED
Apellis Pharmaceuticals
APLS
| $3.63M | 1.35% |
275,000
-100,000
| -27% | -$1.53M |
2018 Q2
2 quarters
|
|
|
AIMT
24
DELISTED
Aimmune Therapeutics
AIMT
| $3.59M | 1.34% |
+150,000
| New | +$3.88M |
2018 Q4
0 quarters
|
|
|
25
Abeona Therapeutics
ABEO
$280M
| $3.21M | 1.2% |
+18,000
| New | +$3.93M |
2018 Q4
0 quarters
|
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q4 2018 Portfolio in Review
As of Q4 2018, Opaleye Management held 61 positions worth $268M, down 32% from $393M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Opaleye Management withdrew a net $27.2M in Q4 2018, closing 14 positions and reducing 11 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $10M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Opaleye Management opened a new position in Avalo Therapeutics worth $6.21M.
- Opaleye Management's largest Q4 2018 buy was Avalo Therapeutics: 759 shares worth $6.21M.
- Opaleye Management added most to Epizyme, Inc in Q4 2018, an estimated $7.06M increase.
- Opaleye Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $6.38M.
- Opaleye Management fully exited Agios Pharmaceuticals in Q4 2018, selling an estimated $10M.
- Opaleye Management's ten largest holdings make up 57% of its $268M portfolio in Q4 2018.
- Opaleye Management opened 14 new positions and closed 14 in Q4 2018.
- Opaleye Management's portfolio value fell 32% quarter-over-quarter to $268M.
Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.